Innovative repurposing formulation for stroke prevention


PRINCIPLE INVESTIGATORS:
Dr.-Ing. Szandor Simmons, Prof. Dr. med. Wolfgang M. Kuebler
Charité

Pharma

Neurology

2024

TRACK 2

SUMMARY

Stroke is the leading cause of cardiovascular morbidity and mortality worldwide, and individuals who have had a stroke are at significantly increased risk of suffering a recurrent secondary stroke. These recurrent events often result in more severe outcomes, including permanent disability and a higher risk of mortality.

Through retrospective analysis of patient data ex vivo and in vivo efficacy testing, the team has identified a treatment that has anticoagulant and antiplatelet potential in inflammatory diseases, coupled with a low risk of ischemia and bleeding.

The overall goal is therefore to develop a tailored formulation of a repurposed drug for the prevention and treatment of recurrent secondary stroke, providing a pathway to improved therapy.

PROJECT GOALS

- Develop a precision repurposing-based formulation tailored to prevent recurrent ischemic stroke
- Evaluate the pharmacokinetics (PK) and efficacy of the new formulation in vivo

LONG-TERM GOALS

- Spin-off
- Perform clinical trials I and II